The key to reducing the mortality from Cryptococcal meningitis, which is a consequent of crag positivity, is early diagnosis of crag in ART-naive AIDS patients prior to initiation of ART therapy and the integration of both ART therapy and primary prophylaxis with Fluconazole; this has been shown to reduce mortality from Cryptococcal meningitis consequent of crag positivity even at CD4 cell
count within the range of <100 cells/[micro]l.
200 and 350) had a two-fold higher rate of their infants becoming infected than those with higher CD4 cell
Shortly after the HIV epidemic became established, it was a strongly held view that the only thing that mattered for understanding HIV pathogenicity was a falling CD4 cell
count, as it was this that led to the opportunistic infections and ultimately to death.
Patients were eligible for the trial if they were 18 or older, had stage 3 or 4 HIV (according to World Health Organization criteria) or a CD4 cell
count below 200 cells per ml (the threshold for an AIDS diagnosis) and had started antiretroviral treatment at the clinic between February 2005 and December 2006.
Hernan, of the Harvard School of Public Health, Boston, and colleagues note that the introduction of combined therapy in 1996 has greatly improved surrogate markers such as CD4 cell
count and HIV RNA levels among patients in the developed world.
An HIV- positive individual is generally given drugs only after his/ her CD4 cell
count falls below 350 or he/ she starts developing symptoms of the disease.
ISENTRESSA (raltegravir), from MSD, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell
Counts in Treatment-NaE[macron]ve Patients up to 144 Weeks When Used in Combination Therapy CAPE TOWN, South Africa--(BUSINESS WIRE)-- Not For Distribution To South African Journalists ISENTRESS A (raltegravir), an integrase inhibitor from Merck Sharpe & Dohme (MSD) was as effective as efavirenz at maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 counts in previously untreated (treatment-naE[macron]ve) patients through 144 weeks in a Phase II study still underway.
The US treatment guidelines  changed in 2007 and now state that antiretroviral therapy should be initiated when the CD4 cell
count falls below 350 cells/[mm.sup.3].
HIV-1 RNA concentrations and CD4 cell
counts are moderately but inconsistently associated with parasitaemia.
adult entering HIV care with a CD4 cell
count of less than 350 has a life expectancy of about 24 years, according to an analysis based on data from a consortium of primary care sites with large HIV caseloads.
The treated patients also had a slightly higher mean CD4 cell
count than did the untreated patients (about 100 cells/mcL higher), which also persisted.
Patients must be three-class experienced with at least two PI-based regimens, and have a CD4 cell
count of equal or less than 200 cells/mm3.